{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"25.9","value":"12.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Estimated by cumulative incidence method. Cumulative incidence of treatment-related mortality with relapse of the original disease as the competing risk will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.\n\ntherapeutic allogeneic lymphocytes: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (DLI)"}],"paramType":"NUMBER","populationDescription":"Patients received at least one DLI treatment.","reportingStatus":"POSTED","timeFrame":"At 2 year","title":"Treatment-related Mortality","type":"SECONDARY","unitOfMeasure":"percentage of patients"}